慢性淋巴细胞白血病转化-Richter综合征治疗进展
Progress of novel therapy in the treatment of chronic lymphocytic leukemia transforming Richter syndrome
张佼佼 1罗菁 1糜坚青1
作者信息
- 1. 上海交通大学医学院附属瑞金医院血液科,上海血液学研究所,国家医学基因重点实验室,国家转化医学研究中心(上海,200025)
- 折叠
摘要
Richter综合征是一种在慢性淋巴细胞白血病/小细胞淋巴瘤(chronic lymphocytic leukemia/small lymphocytic lymphoma,CLL/SLL)基础上发展的侵袭性淋巴瘤.目前大部分转化患者预后极差,特别是与CLL/SLL存在克隆相关的转化患者对传统化学免疫治疗疗效不理想.通过联合应用新型靶向药物以及细胞免疫治疗等手段,在一定程度上可以改善这部分患者的疗效;同时也为年龄适合的患者创造了获得移植的机会.本文我们主要阐述了 CLL/SLL转化为Richter综合征的治疗进展.
Abstract
Richter syndrome refers to an aggressive lymphoma that develops based on chronic lymphocytic leukemia/small lymphocytic lymphoma(CLL/SLL).The majority of transformed patients currently have an infe-rior prognosis,and in particular,conventional chemoimmunotherapy showed poor efficacy in clonal related pa-tients:This group of patients may benefit from combinations of novel targeted agents and/or cellular immunother-apy.These new strategies also offer opportunities for patients who are age-appropriate for transplantation.In this review,we focus on current advances related to the therapeutic strategies available for this disease.
关键词
Richter综合征/靶向药物/免疫治疗/移植/治疗进展Key words
Richter syndrome/targeted agents/immunotherapy/transplantation/therapeutic progress引用本文复制引用
出版年
2024
NETL
NSTL
万方数据